Humanigen Collaborates With Thermo Fisher To Expand Manufacturing Capacity For Lenzilumab

(RTTNews) - Humanigen, Inc. (HGEN) announced a strategic collaboration with Thermo Fisher Scientific, to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19. This multi-year manufacturing partnership adds to the company's large scale commercial production efforts, including recently announced partnerships with Lonza and Catalent. Thermo Fisher will begin the technical transfer of the lenzilumab bulk drug substance process and commercial scale production could begin before the end of the current year.

Cameron Durrant, CEO of Humanigen said: "Thermo Fisher provides biologics manufacturing expertise and scalable capacity to further support our production and growth trajectory."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More